DexCom's over-the-counter continuous glucose monitor, Stelo, has received FDA clearance for pediatric use in children aged 2 years and older. This strategic expansion allows children who do not use insulin to access real-time glucose monitoring through the Stelo biosensor. The approval, finalized in mid-June, broadens the market reach for DexCom’s non-prescription glucose monitoring technology.
